Monitoring Eosinophil Trends and Access to Biologics in Asthma Treatment

This chapter explores the management of eosinophils in patients being treated with dupilumab for asthma, focusing on the expected eosinophil trends in the first 16 weeks. It also highlights the importance of equitable access to biologics for underserved populations and discusses the challenges related to cost and insurance coverage.